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Background/aim: In this study, the in vitro and in vivo effectiveness of caffeic acid (3,4-dihydroxycinnamic acid) phenethyl ester
(CAPE) in combination with bortezomib, a proteasome inhibitor, was explored in multiple myeloma (MM) cells.
Materials and methods: The cytotoxic effects of CAPE and bortezomib were determined by XTT cell proliferation assay. Apoptosis
levels were analyzed with annexin V-fluorescein isothiocyanate, nuclear factor kappa beta (NF-κB) was analyzed with electrophoretic
mobility-shift assay, and interleukin (IL)-6 levels were analyzed with enzyme-linked immunosorbent assay to evaluate CAPE’s
mechanism of action. To investigate the in vivo effectiveness of CAPE and bortezomib, an experimental plasmacytoma model was
induced in BALB/c mice.
Results: Increasing concentrations of CAPE and bortezomib decreased the proliferation of ARH-77 cells in a dose-dependent manner.
With doses of CAPE IC50, a significant increase in apoptosis and a significant decrease in IL-6 levels were detected. The NF-κB DNAbinding activity decreased compared to the basal ARH-77 level. The administration of CAPE alone or in combination with bortezomib
increased the rate of survival compared to the control group.
Conclusion: We think that our study, which is the first to demonstrate the in vitro and in vivo effectiveness of the combined use of CAPE
and bortezomib, will be a pioneer for future human applications of CAPE in MM.
Key words: Caffeic acid phenethyl ester, bortezomib, multiple myeloma, in vitro cytotoxicity, in vivo study

1. Introduction
Multiple myeloma (MM) is a hematologic cancer
characterized by uncontrolled monoclonal plasma cell
proliferation (1). MM is currently an incurable B-cell
malignancy that accounts for nearly 10% of human
hematopoietic cancers and 1% of all human cancers (2).
Presently, the 2 most effective treatment choices for patients
with MM are tandem high-dose chemotherapy followed by
autologous stem cell infusion, or allogeneic hematopoietic
* Correspondence: ealtayli@gata.edu.tr
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stem cell transplantation after myeloablative therapy
or reduced-intensity conditioning (1). The proteasome
inhibitor bortezomib is a novel drug with promising
efficacy, even for patients with relapsed refractory MM
(3,4). Nevertheless, these choices are not appropriate in
all patients, and drug resistance often increases over time.
Consequently, there is a need for new treatment options
that can augment the effectiveness of current treatments
(5,6).
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Caffeic acid (3,4-dihydroxycinnamic acid) phenethyl
ester (CAPE) is an active component of honey bee propolis
extract. Propolis is a resinous and waxy substance made by
bees in the natural environment that forms the honeycomb,
and, depending on its source, varies from yellow to
dark brown in color. Although the chemical structure of
propolis varies depending on the flora in the region where
the bees reside, it is not fully understood. At present, more
than 300 compounds have been found in the structure
of propolis. Propolis is used as a traditional medicine in
the Far East (7). Recently, CAPE has been shown to act
as an antiviral (8), antiinflammatory (9), antitumoral (10),
neuroprotective (11), antioxidant (12,13), antiallergic (14),
and antiatherosclerotic (15) agent in diverse systems (16).
CAPE has cytotoxic, apoptotic, and antiproliferative effects
on various tumor cells, both in vivo and in vitro (17,18).
CAPE is a well-known and well-documented inhibitor of
interleukin-6 (IL-6) and the transcription factor nuclear
factor kappa beta (NF-κB) (19,20). IL-6 is a key growth
and survival factor for murine plasmacytoma cells, human
myeloma cells, and myeloma cell lines. Additionally, IL-6
is also a major morbidity factor for patients with MM
(2,21). Although the precise role of NF-κB activation in
the pathogenesis of MM has not been fully characterized,
MM cell adhesion to bone marrow stromal cells induces
NF-κB-dependent upregulation of the transcription of
IL-6, which is a growth and antiapoptotic factor in MM
(22,23).
Transcription NF-κB is the generic name for a family
of dimeric factors that bind to many different promoters
to initiate transcription (24). The most common form of
NF-κB is the p65/p50 heterodimer, while the other forms
occur less frequently (25). Loss of the normal regulation
of NF-κB has been found to be a major contributor to
unregulated growth, resistance to apoptosis, and the
predisposition to metastasize, which are observed in many
cancers. Constitutive NF-κB activity has been identified in
many different tumors, such as MM, acute lymphoblastoid
leukemia, prostate cancer, breast cancer, and colon cancer
(26–28).
The human MM cell line ARH-77 has been used
in many in vitro cytotoxicity studies (29–31). We have
previously shown the cytotoxic effect of CAPE on the
ARH-77 cell line (18). However, the cytotoxic effect of the
combination of CAPE and bortezomib on ARH-77 cells
has not yet been investigated.
The present study aimed to investigate the in vitro
and in vivo cytotoxic effects of CAPE and bortezomib in
MM cells. We had already proven, for the first time, the
antitumor effectiveness of CAPE, found in propolis, on
MM cells in an in vitro study (18). The concurrent use of
bortezomib, which is used in the treatment of MM, with
CAPE has never been attempted.

2. Materials and methods
2.1. Reagents and drug
CAPE,
dimethyl
sulfoxide
(DMSO),
pristane
(2,6,10,14-tetramethylpentadecane, 95% pure), and
the
2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2htetrazolium-5-carboxanilide (XTT) cell proliferation assay
were manufactured by Sigma-Aldrich (USA). Bortezomib
was manufactured by Janssen-Cilag (UK). All materials
were purchased commercially.
2.2. In vitro studies
2.2.1. Cell lines and culture conditions
The ARH-77 MM cell line was used in frozen form in a
liquid nitrogen system at the Gülhane Military Medical
Academy Research and Development Center, Medical and
Cancer Research Laboratory. The ARH-77 MM cell line
was previously purchased from the American Type Culture
Collection (USA). ARH-77 is a floating human plasma cell
leukemia cell line that secretes IgGκ. The ARH-77 cell line
was maintained at 37 °C in a 5% CO2 medium in RPMI
1640 (GIBCO, USA), which was supported with a solution
of 10% fetal bovine serum (Hyclone Laboratory, USA), 2
mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL
streptomycin (GIBCO).
2.2.2. Cell viability assay and isobologram analysis
For the in vitro study, IC50 values (drug concentration that
restrains cell proliferation by 50%) were obtained by the
XTT method at hours 24 and 48 following administration
of varying doses of CAPE and bortezomib to the MM cell
line (ARH-77). In summary, 96-well plates were seeded
with 2 × 104 cells/well including 100 µL of growth medium
in the absence (0.1% DMSO) or presence of increasing
concentrations of the drugs (CAPE concentrations of 5, 10,
20, 40, 80, and 160 µg/mL and bortezomib concentrations
of 1, 10, 20, 30, 50, and 100 nM). At the end of incubation,
the XTT test was used to assess cell viability. Shortly
thereafter, 96-well plates were seeded with 2 × 104 cells/
well including 200 mL of growth medium in the presence
or absence of increasing concentrations of the drugs. The
cells were incubated at 37 °C in 5% CO2. After 72 h, cell
suspensions were treated with 50 mL of XTT reagent for 4
h. Specimens were detected spectrophotometrically. Each
study was repeated 3 times.
After increased doses of CAPE and bortezomib were
given individually and in combination, the decrease in
viability resulting from using doses of CAPE IC50 and
bortezomib IC50 were evaluated with CalcuSyn isobologram
analysis. The combination index (CI), a measurement of
the combined action of both drugs, is used as a method
of determining the median effect. A CI value of <1 shows
a synergistic effect (0.1–0.5 potent synergism; <0.1 very
potent synergism); a CI value of 1 shows an additive effect;
and a CI value of >1 shows an antagonistic effect (3.3–10
potent antagonism, >10 very potent antagonism).
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2.2.3. Electrophoretic mobility-shift assay for NF-κB
Electrophoretic mobility-shift assay was performed on
ARH-77 cells stimulated with 0.1% DMSO, CAPE IC50,
or bortezomib IC50 with 0.1% DMSO for 24 h. For the
isolation of nuclear and cytoplasmic proteins, the cells
were washed twice with ice-cold phosphate-buffered saline
(PBS) and resuspended in 1 mL of Buffer A containing 20
mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 1 mM
DTT, 1.5 mM MgCl2, and 1X protease inhibitors; it was
then incubated on ice for 30 min. The cells were vortexed
at a high speed for 15 s, and then, following the addition
of 0.25% NP40 (AppliChem, Germany), the cells were
incubated on ice for another 5 min and vortexed for 5 s.
Supernatants were obtained after centrifugation at 12,000
× g for 1 min at 4 °C. The remaining nuclear pellet was
washed with 200 µL of Buffer A to remove all cytoplasmic
proteins and centrifuged. The pellet was resuspended in
200 µL of Buffer B containing 20 mM HEPES, 10 mM KCl,
0.1 mM EDTA, 1 mM DTT, 1.5 mM MgCl2, 0.5 M NaCl,
and 25% glycerol and incubated on ice for 30 min. The
lysate was centrifuged for 10 min at 12,000 × g at 4 °C. The
supernatant was accepted as the nuclear fraction.
The NF-κB DNA-binding consensus sequences were
prepared in the database at http://www.ncbi.nlm.nih.
gov/nucleotide and purchased commercially (İontek,
Turkey). Binding reactions were prepared with NFκB-binding consensus sequences containing marked
probes. Afterwards, these reactions were carried out in
a polyacrylamide gel system and transferred to nylon
membranes. To identify the mark on the probes, the nylon
membranes were incubated in the reaction medium.
Probes bound with NF-κB protein were visualized with
chemiluminescence.
2.2.4. Measurement of IL-6 by enzyme-linked
immunosorbent assay
Enzyme-linked immunosorbent assay was performed
on ARH-77 cells stimulated with 0.1% DMSO, CAPE
IC50, or bortezomib IC50 with 0.1% DMSO for 24 h. The
supernatant’s IL-6 levels were measured with the enzyme
immunoassay method. The absorbance readings were
made with the Alisei Quality System device (SEAC Radim
Group, Italy). IL-6 concentrations were calculated by
drawing standard curves.
2.2.5. Measurement of apoptosis by annexin V and flow
cytometry
The fluorescein isothiocyanate (FITC) Annexin V
Apoptosis Detection Kit protocol (BD Pharmingen, USA)
was used for this study. CAPE IC50, bortezomib IC50, and,
for control purposes, 0.1% DMSO were applied to ARH77 cells for 24 h. Cells were centrifuged at 800 rpm for 5
min and the supernatant was removed. The cell pellet, at
a final concentration of 1 × 106 cells/mL, was dissolved
with 1X annexin V binding buffer. A 200-µL sample was
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taken from this suspension and vortexed after adding 5 µL
of annexin V-FITC and 5 µL of propidium iodide. It was
then left to incubate at room temperature for 15 min. At
the end of incubation, 400 µL of annexin V binding buffer
was added and vortexed. Thirty minutes after readings
were made using flow cytometry (BD FACS CANTO), the
results were analyzed.
2.3. In vivo studies
2.3.1. Animals
Female BALB/c mice (5–6 weeks old) were provided by
the Gülhane Military Medical School Research Center,
Ankara, Turkey. The mice were housed in a controlled
environment with a 12-h light/dark cycle at a temperature
of 24 ± 2 °C and humidity of 55 ± 10%. They were given
pellet chow and water ad libitum. Ethical approval for the
animal study was received from the Animal Research and
Care Committee at Gülhane Military Medical School.
2.3.2. Induction and diagnosis of mouse plasmacytoma
The mouse plasmacytoma (MPC) model was prepared
as previously defined (38). In brief, MPC was induced in
mice by intraperitoneal injections of 0.5 mL of pristane on
days 0, 60, and 120. Controls were given an equal amount
of PBS. Full groups were maintained under surveillance
for 400 days. One hundred days after the first injection of
pristane, mice were inspected for the presence of ascites.
They were examined by paracentesis. The diagnosis of
plasmacytoma was made according to previously defined
criteria (32).
2.3.3. Study protocol
A total of 124 mice were registered in this study and they
were randomly assigned to 8 experimental groups: Group
I (n = 20), pristane-induced alone; Group II (n = 20),
CAPE started after the appearance of pristane-induced
MPC; Group III (n = 20), bortezomib started after the
appearance of pristane-induced MPC; Group IV (n =
20), CAPE and bortezomib started after the appearance
of pristane-induced MPC; Group V (n = 11), CAPE given
alone; Group VI (n = 11), bortezomib given alone; Group
VII (n = 11), PBS given alone; and Group VIII (n = 11),
nothing given.
2.3.4. Histopathological evaluation
After 400 days of observation, the mice were sacrificed
by cervical dislocation and the intraabdominal organs
(spleen, liver, and kidneys) were fixed with 10% formalin
and embedded in paraffin. Sections 4 µm long were
taken, stained with hematoxylin and eosin, and examined
for plasmacytoma. Histopathological diagnosis of
plasmacytoma was made according to previously specified
criteria (33).
2.4. Statistical analysis
At the end of the CAPE and bortezomib cytotoxic studies,
the IC50 values for the 2 agents were calculated using the

regression model. The IL-6 and apoptosis levels of the
different groups were compared using one-way variation
analysis. Dunnett and Bonferroni corrections were used
as post hoc tests. The comparison of the survival times
between the treatment groups was performed using
Kaplan–Meier analysis; log-rank statistics were calculated.
Isobologram curves were drawn and combination indexes
were calculated. P < 0.05 was considered statistically
significant. SPSS 15 was used for statistical analysis.
3. Results
3.1. Cytotoxic effects of CAPE and bortezomib on ARH77 cells
In this study, it was shown that increasing concentrations
of CAPE (5–100 µg/mL) decreased the proliferation of
ARH-77 cells in a dose-dependent manner compared to
untreated controls (Figure 1). As a result, the IC50 value of
CAPE was determined to be 28 and 21 µg/mL at 24 and 48
h, respectively. Increasing intracellular concentrations of
bortezomib (1–100 nM) also inhibited cell proliferation in
a dose-dependent manner compared to untreated controls
(Figure 2). The IC50 value of bortezomib was calculated as
13 and 11 nM for ARH-77 cells at 24 and 48 h, respectively.
3.2. Combination effects of CAPE and bortezomib on
ARH-77 cell proliferation
Combination studies of CAPE with bortezomib were also
carried out to determine whether there was an increase in
the antiproliferative effects of CAPE on ARH-77 cells. Cell
proliferation data showed that both the increased dosage
of bortezomib with the IC50 constant dose of CAPE and the
increased dosage of CAPE with the IC50 constant dose of
bortezomib increased the cytotoxic effectiveness compared
to 0.1% DMSO in ARH-77 cells. The increased dosage of
bortezomib and the IC50 constant dose of CAPE had very

Percentage of cell proliferation in XTT

120
24 h

100

48 h

80
60
40
20
0

Control

5

10

20

40

80

160

Concentration of CAPE (µg/mL)

Figure 1. Percentage of alive cells at different CAPE
concentrations.

Percentage of cell proliferation in XTT
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120
24 h
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80
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20
0

Control

1
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50
Concentration of Bortezomib (nM)

100

Figure 2. Percentage of alive cells at different bortezomib
concentrations.

strong synergism at both 24 h (CI (ED50): 0.00067) and
48 h (CI (ED50): 0.00295) in the ARH-77 cell line (Figure
3A). Similarly, the increased dosage of CAPE and the IC50
constant dose of bortezomib had strong synergism at both
24 h (CI (ED50): 0.58040) and 48 h (CI (ED50): 0.51044) in
the ARH-77 cell line (Figure 3B).
3.3. Effect of CAPE on apoptosis
To investigate whether there was any decrease in cell
viability caused by apoptosis, we analyzed apoptosis using
annexin V with flow cytometry. A significant increase in
apoptosis was observed in the ARH-77 MM cells given
CAPE IC50 doses (P < 0.001). These results show that
CAPE does induce apoptosis in ARH-77 cells (P < 0.001)
(Table 1).
3.4. CAPE inhibits NF-κB-binding activity and IL-6
levels
To investigate the mechanisms underlying CAPEinduced apoptosis, we examined the effect of CAPE
on the expression of NF-κB and the NF-κB-dependent
upregulation of IL-6. The NF-κB DNA-binding activity
in ARH-77 MM cells that were given doses of CAPE IC50
and bortezomib IC50 were found to be decreased compared
to basal ARH-77 levels (Figure 4). Similarly, a significant
reduction was detected in IL-6 levels (P < 0.001). These
results show that NF-κB inhibition by CAPE does induce
apoptosis in ARH-77 cells.
3.5. Assay of in vivo examination
The appearances of normal mice and mice with
plasmacytoma are compared in Figure 5. Abdominal
distention is observed due to intraabdominal ascitic fluid
in mice with experimentally induced plasmacytoma.
The appearances of the intraabdominal organs (liver,
kidneys, and spleen) of the normal mice and mice with
plasmacytoma are compared in Figure 6.
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Figure 3A. Increased dosage of bortezomib and IC50 constant dose of CAPE on the ARH-77 cell line.
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Figure 3B. Increased dosage of CAPE and IC50 constant dose of bortezomib on the ARH-77 cell line.
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Table 1. Comparison of percentage of apoptotic cells between groups.
n

Mean

SDP*

Control

8

1.9000

0.34059

Bortezomib

8

5.6000

0.48166

CAPE

8

13.2000

0.98793

<0.001 a,b,c

* ANOVA test result.
Statistically significant differences between: acontrol versus bortezomib group, bcontrol
versus CAPE group, cbortezomib group versus CAPE group.

Figure 5. Abdomen was markedly distended in mouse with
plasmacytoma (A) as compared to normal mouse (B).

Figure 4. While NF-κB signal was obtained in the control group
consisting of only the ARH-77 cell line (shown by an arrow), NFκB binding signal could not be obtained in ARH-77 cells treated
with CAPE and bortezomib.

In the plasmacytoma group, plasma cell infiltration was
observed in the peritoneal surfaces of the abdominal cavity.
Those plasma cells were mature (Figure 7). Additionally,
fibrosis, calcification, and inflammation were also
associated with the plasma cells. However, no differences
were observed for fibrosis or inflammation in either the
vehicle- or CAPE-treated animals. In other tissues and
organs, including the liver, spleen, and kidneys, no damage
was observed during histopathological examination.

Figure 6. A) Macroscopic appearance of multiple oil granulomas
(arrows) on the surface of abdominal organs in mouse with
plasmacytoma. B) Normal appearance of abdominal organs
including liver, kidneys, and spleen in the control group.
Magnification of images 1/1.
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Figure 7. Atypical plasma cell infiltration in tissue samples
obtained from mice with experimentally induced plasmacytoma.

The mean survival rate of mice with experimentally
induced plasmacytoma is shown in Table 2. Although
not statistically significant, the survival rate was longer in
groups in which CAPE or bortezomib were administered,
and particularly for the group in which CAPE and
bortezomib were administered together.
4. Discussion
In this study, we investigated the in vitro and in vivo
cytotoxic effects of CAPE, which is still an experimental
drug, and bortezomib, which is currently used as a drug.
Inclusion of bortezomib in our study enabled us to evaluate
the synergistic effects of the agents in terms of cytotoxic
effects and to use CAPE as a positive control when needed.

In our study, we demonstrated that CAPE and
bortezomib have in vitro cytotoxic effects on the ARH-77
MM cell line and that, when they were used in combination,
there was a strong synergistic effect. In addition, our in
vitro studies showed that CAPE inhibited NF-κB DNAbinding activity in a dose- and time-dependent manner in
ARH-77 cells. It also significantly reduced IL-6 levels and
induced apoptosis.
NF-κB is misregulated in many different types of
human cancers and is found to be chronically active in
many cancers (34,35). NF-κB activity protects cancer
cells from apoptosis and induces their proliferation. NFκB inhibition, in connection with increased apoptosis,
establishes a balance between dead and viable cells (36).
Therefore, we think that the reduction of NF-κB DNAbinding activity caused by CAPE is significant.
IL-6 is the major growth and survival factor for MM
cells (37). Although the role of NF-κB in MM pathogenesis
is not definite, it has been shown that stimulation of the
transcription of the growth and antiapoptotic factor IL-6 is
dependent on NF-κB (38). For this reason, it is extremely
significant that CAPE reduced IL-6 levels in the MM cell
lines.
There is only one study that has investigated the in
vitro cytotoxic effects of CAPE on ARH-77 MM cell lines
(18). In that study, which had results that supported our
own findings, Koru et al. demonstrated that CAPE, in a
100 µg/mL concentration over 72 h, inhibited cell growth
by 90.4% and displayed a cytotoxic effect of 80.4%. In the
same study, apoptosis stimulation was observed in 92.3%
of the cells treated with a 22.5 µg/mL concentration of
CAPE over 72 h and CAPE was also shown to inhibit IL-6

Table 2. Mean survival in mice of plasmacytoma groups (days). PCT = Plasmacytoma,
BOR = bortezomib.
Group

N

Mean

Standard error

PCT

10

269.000

12.234

PCT + CAPE

10

284.300

10.305

PCT + BOR

10

287.500

9.762

PCT + CAPE + BOR

10

298.500

1.423

PBS

10

298.600

1.328

CAPE

10

285.600

13.661

BOR

10

281.100

17.930

No treatment

10

300.000

0.000

P*
*: Log-rank test result.
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secretion at the IC50 concentration. In addition, various
in vitro studies have been conducted investigating the
cytotoxic effects of CAPE. Chen et al. investigated the
relationship between CAPE-induced alterations of the
redox state and apoptosis in human leukemic HL-60 cells.
In that study, CAPE was shown to inhibit cell growth in
70.3% of cells at a 6 µg/mL concentration by the end of
48 h as compared to the control group and caused DNA
fragmentation at the same concentration after 6 h (17).
In the in vitro studies conducted by Onori et al., CAPE
was shown to reduce the growth of cholangiocarcinoma
by NF-κB inhibition and apoptosis induction (39). Other
studies have also shown CAPE to inhibit NF-κB and to
have cytotoxic effects on various cancer cell lines (40,41).
According to the in vivo experimental results of
our study, although not statistically significant, CAPE
was shown to increase the survival rate of mice with
experimentally induced plasmacytoma alone or in
combination with bortezomib. There are no available in
vivo studies investigating the effects of CAPE on MM cells.
However, results supporting our study have been reported
in various studies investigating the in vivo effects of CAPE
on various cancer models (42,43). Among them is the in
vivo study by Onori et al. in which, after intraperitoneal

CAPE at 10 mg/kg was administered to BALB/c mice,
tumor growth was found to be reduced within 77 days, the
latent period of the tumor was increased 2-fold, and no
differences were observed in the fibrosis or inflammation
in either the carrier- or CAPE-treated animals with no
other tissue/organ damage.
In conclusion, CAPE was shown to prevent MM
cell line proliferation when administered alone and was
shown to have a very strong synergistic cytotoxic effect
when administered in combination with bortezomib.
In mice with experimentally induced plasmacytoma,
although not statistically significant, CAPE used alone or
in combination with bortezomib was shown to prolong
the life span compared to the control group. We were not
surprised to see the difference between in vitro studies
performed in the laboratory (artificial conditions) and in
vivo studies performed in a living organism. However, the
significance of these findings will become more apparent
once an in vivo study is conducted with a larger number
of test animals or with xenograft models. Our study is the
first to prove the in vivo and in vitro effectiveness of the
combined use of CAPE and bortezomib. We think that
our study will serve as a pioneer study for future human
studies regarding CAPE.
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